The potential of Beclin 1 as a therapeutic target for the treatment of breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Yoon Yang | - |
dc.contributor.author | Lee, Yu Kyung | - |
dc.contributor.author | Koo, Ja Seung | - |
dc.date.accessioned | 2022-07-15T18:24:36Z | - |
dc.date.available | 2022-07-15T18:24:36Z | - |
dc.date.created | 2021-05-14 | - |
dc.date.issued | 2016-02 | - |
dc.identifier.issn | 1472-8222 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/155104 | - |
dc.description.abstract | Introduction: Beclin 1 plays a crucial role in autophagy via the Beclin 1 interactome, and is involved in various biological processes such as protein sorting, chemokinesis, and cell death. Via these biologic functions, Beclin 1 contributes to both tumor suppression and tumor progression.Areas covered: Beclin 1 plays a key biologic function on cell homeostasis and affects tumorigenesis. In this review, detailing up-to-date knowledge on the tumorigenic role of Beclin 1, its implication in breast cancer, and its utility as a breast cancer-specific drug target is discussed.Expert opinion: Because Beclin 1 is expressed in breast cancer cells, Beclin 1 could be a unique, effective drug target for the prevention and treatment of breast cancer. However, the expression of Beclin 1 varies according to cancer molecular subtypes, and Beclin 1 is involved in both breast cancer suppression and tumor progression; therefore, the decision of using a Beclin 1 inducer or inhibitor should be made based on breast cancer stage and subtype. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.title | The potential of Beclin 1 as a therapeutic target for the treatment of breast cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jung, Yoon Yang | - |
dc.identifier.doi | 10.1517/14728222.2016.1085971 | - |
dc.identifier.scopusid | 2-s2.0-84957936470 | - |
dc.identifier.wosid | 000370868700003 | - |
dc.identifier.bibliographicCitation | EXPERT OPINION ON THERAPEUTIC TARGETS, v.20, no.2, pp.167 - 178 | - |
dc.relation.isPartOf | EXPERT OPINION ON THERAPEUTIC TARGETS | - |
dc.citation.title | EXPERT OPINION ON THERAPEUTIC TARGETS | - |
dc.citation.volume | 20 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 167 | - |
dc.citation.endPage | 178 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기 학술지(Review) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | CASPASE-MEDIATED CLEAVAGE | - |
dc.subject.keywordPlus | REGULATES AUTOPHAGY | - |
dc.subject.keywordPlus | LOBULAR CARCINOMA | - |
dc.subject.keywordPlus | MOLECULAR SUBTYPE | - |
dc.subject.keywordPlus | POOR-PROGNOSIS | - |
dc.subject.keywordPlus | CELL | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | PROTEINS | - |
dc.subject.keywordPlus | GENE | - |
dc.subject.keywordAuthor | Autophagy | - |
dc.subject.keywordAuthor | Beclin 1 | - |
dc.subject.keywordAuthor | Breast cancer | - |
dc.subject.keywordAuthor | Targeted drug therapy | - |
dc.identifier.url | https://www.tandfonline.com/doi/full/10.1517/14728222.2016.1085971 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.